SA521420951B1 - مركبات ترايازول تعمل كمثبطات للجليكولات أوكسيداز - Google Patents
مركبات ترايازول تعمل كمثبطات للجليكولات أوكسيدازInfo
- Publication number
- SA521420951B1 SA521420951B1 SA521420951A SA521420951A SA521420951B1 SA 521420951 B1 SA521420951 B1 SA 521420951B1 SA 521420951 A SA521420951 A SA 521420951A SA 521420951 A SA521420951 A SA 521420951A SA 521420951 B1 SA521420951 B1 SA 521420951B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- oxidase inhibitors
- glycolate oxidase
- triazole
- useful
- pharmaceutically acceptable
- Prior art date
Links
- 102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 title abstract 2
- 108010062584 glycollate oxidase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003852 triazoles Chemical class 0.000 title 1
- 208000000913 Kidney Calculi Diseases 0.000 abstract 1
- 206010029148 Nephrolithiasis Diseases 0.000 abstract 1
- 208000004777 Primary Hyperoxaluria Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- -1 triazole carboxylic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694918P | 2018-07-06 | 2018-07-06 | |
| US201962827573P | 2019-04-01 | 2019-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521420951B1 true SA521420951B1 (ar) | 2024-03-24 |
Family
ID=67441692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521420951A SA521420951B1 (ar) | 2018-07-06 | 2021-01-03 | مركبات ترايازول تعمل كمثبطات للجليكولات أوكسيداز |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11401246B2 (https=) |
| EP (1) | EP3817816A1 (https=) |
| JP (1) | JP7348705B2 (https=) |
| KR (1) | KR102865323B1 (https=) |
| CN (1) | CN112399873B (https=) |
| AU (1) | AU2019297523B2 (https=) |
| BR (1) | BR112021000050A2 (https=) |
| CO (1) | CO2021001277A2 (https=) |
| IL (1) | IL279952B2 (https=) |
| MX (1) | MX2021000051A (https=) |
| PE (1) | PE20210859A1 (https=) |
| SA (1) | SA521420951B1 (https=) |
| SG (1) | SG11202012930RA (https=) |
| WO (1) | WO2020010309A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021000050A2 (pt) | 2018-07-06 | 2021-04-06 | Orfan Biotech Inc. | Inibidores de triazol glicolato oxidase |
| AU2020376792B2 (en) | 2019-11-01 | 2025-10-02 | Lilac Therapeutics, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
| EP4087836B1 (en) * | 2020-01-08 | 2025-10-08 | Cantero Therapeutics, Inc. | Processes for preparing triazole glycolate oxidase inhibitors |
| WO2022066933A1 (en) * | 2020-09-24 | 2022-03-31 | Chinook Therapeutics Canada, Inc. | Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof |
| JP2024538054A (ja) * | 2021-10-11 | 2024-10-18 | カンテロ セラピューティクス，インコーポレイティド | 高シュウ酸尿症及び腎結石の治療のための１ｈ－１，２，３－トリアゾール－４－カルボン酸 |
| WO2024109917A1 (zh) * | 2022-11-25 | 2024-05-30 | 西藏海思科制药有限公司 | 一种三唑衍生物及其在医药上的应用 |
| WO2024212137A1 (en) * | 2023-04-12 | 2024-10-17 | Cantero Therapeutics, Inc. | Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0774218B2 (ja) * | 1987-03-02 | 1995-08-09 | 第一製薬株式会社 | ベンゾピラノトリアゾ−ル誘導体 |
| US6187326B1 (en) | 1998-12-29 | 2001-02-13 | Thomas T. Yamashita | Soil amendment composition |
| US7022702B2 (en) | 2000-04-07 | 2006-04-04 | Qlt Inc. | Antiproliferative 1,2,3-thiadiazole compounds |
| CA2546353A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| CN101307307A (zh) * | 2008-07-11 | 2008-11-19 | 华东理工大学 | 一种乙醇酸氧化酶制剂、制备方法及应用 |
| WO2013104573A1 (en) | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Pyridazine amide compounds and their use as syk inhibitors |
| JP5455279B1 (ja) | 2012-10-25 | 2014-03-26 | アサヒグループホールディングス株式会社 | ラテックスの増産方法 |
| WO2014113485A1 (en) | 2013-01-15 | 2014-07-24 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| US9392796B2 (en) | 2013-03-15 | 2016-07-19 | Spogen Biotech Inc. | Plant growth-promoting bacteria and methods of use |
| FR3021843B1 (fr) | 2014-06-06 | 2016-07-08 | Lesaffre & Cie | Methode et composition pour ameliorer la productivite de plantes non legumineuses |
| JP5866035B1 (ja) | 2015-01-08 | 2016-02-17 | アサヒグループホールディングス株式会社 | 有効分げつ促進方法 |
| JP7148241B2 (ja) | 2015-03-19 | 2022-10-05 | 三菱商事ライフサイエンス株式会社 | 植物の生長促進や根伸長促進効果且つ付加価値向上効果を有する酵母抽出物 |
| EP3386949A4 (en) * | 2015-12-07 | 2019-11-20 | Wake Forest University Health Sciences | GLYCOLATE OXIDASE INHIBITORS AND METHOD FOR USE FOR THE TREATMENT OF NIERSTEIN |
| MX2020006414A (es) | 2017-12-29 | 2020-09-17 | Biomarin Pharm Inc | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| EP3731840A4 (en) | 2017-12-29 | 2021-09-15 | Orfan Biotech Inc. | NADPH OXIDASE INHIBITORS AND THEIR USE |
| US11389456B2 (en) | 2018-02-23 | 2022-07-19 | Oxalurx, Inc. | Compounds and methods for treating oxalate-related diseases |
| BR112021000050A2 (pt) | 2018-07-06 | 2021-04-06 | Orfan Biotech Inc. | Inibidores de triazol glicolato oxidase |
| CA3143334A1 (en) | 2019-06-19 | 2020-12-24 | Biomarin Pharmaceutical Inc. | Glycolate oxidase inhibitors for the treatment of disease |
-
2019
- 2019-07-05 BR BR112021000050-0A patent/BR112021000050A2/pt unknown
- 2019-07-05 SG SG11202012930RA patent/SG11202012930RA/en unknown
- 2019-07-05 EP EP19745452.3A patent/EP3817816A1/en active Pending
- 2019-07-05 US US17/255,600 patent/US11401246B2/en active Active
- 2019-07-05 IL IL279952A patent/IL279952B2/en unknown
- 2019-07-05 PE PE2021000011A patent/PE20210859A1/es unknown
- 2019-07-05 CN CN201980045610.4A patent/CN112399873B/zh active Active
- 2019-07-05 AU AU2019297523A patent/AU2019297523B2/en active Active
- 2019-07-05 WO PCT/US2019/040690 patent/WO2020010309A1/en not_active Ceased
- 2019-07-05 JP JP2021521945A patent/JP7348705B2/ja active Active
- 2019-07-05 MX MX2021000051A patent/MX2021000051A/es unknown
- 2019-07-05 KR KR1020217003486A patent/KR102865323B1/ko active Active
-
2021
- 2021-01-03 SA SA521420951A patent/SA521420951B1/ar unknown
- 2021-02-05 CO CONC2021/0001277A patent/CO2021001277A2/es unknown
-
2022
- 2022-06-17 US US17/843,455 patent/US20230143491A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL279952A (en) | 2021-03-01 |
| AU2019297523B2 (en) | 2025-04-17 |
| EP3817816A1 (en) | 2021-05-12 |
| CN112399873B (zh) | 2024-10-25 |
| BR112021000050A2 (pt) | 2021-04-06 |
| SG11202012930RA (en) | 2021-01-28 |
| PE20210859A1 (es) | 2021-05-18 |
| KR20210041564A (ko) | 2021-04-15 |
| JP7348705B2 (ja) | 2023-09-21 |
| WO2020010309A9 (en) | 2020-01-30 |
| US20230143491A1 (en) | 2023-05-11 |
| US20210403439A1 (en) | 2021-12-30 |
| KR102865323B1 (ko) | 2025-09-26 |
| US11401246B2 (en) | 2022-08-02 |
| WO2020010309A1 (en) | 2020-01-09 |
| JP2021530560A (ja) | 2021-11-11 |
| MX2021000051A (es) | 2021-03-25 |
| CN112399873A (zh) | 2021-02-23 |
| AU2019297523A1 (en) | 2021-02-25 |
| IL279952B1 (en) | 2024-07-01 |
| CA3104529A1 (en) | 2020-01-09 |
| IL279952B2 (en) | 2024-11-01 |
| CO2021001277A2 (es) | 2021-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521420951B1 (ar) | مركبات ترايازول تعمل كمثبطات للجليكولات أوكسيداز | |
| PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
| MX2025002170A (es) | Inhibidores de kras g12c | |
| PH12021500014A1 (en) | Fused ring compounds | |
| PH12022550399A1 (en) | MTA-Cooperative PRMT5 Inhibitors | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| AU2020281332A8 (en) | Dna-dependent protein kinase inhibitor | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| CR20200184A (es) | Compuestos útiles para inhibir a cdk7 | |
| WO2017109488A8 (en) | Cyanopyrrolidine derivatives as inhibitors for dubs | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| CA3139148A1 (en) | Crystalline salt forms of a kinase inhibitor | |
| PH12021550883A1 (en) | Crystalline salts of a plasma kallikrein inhibitor | |
| MX2021002878A (es) | Inhibidores de cd73 y usos farmaceuticos de los mismos. | |
| EP4691564A3 (en) | Neurokinin inhibitors such as aprepitant for treating non small cell lung carcinoma or breast cancer without mutations | |
| IL320582A (en) | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | |
| AU2020378127A8 (en) | Compounds as CD73 inhibitors | |
| WO2019195641A3 (en) | 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof |